Recent Updates
Recently added Catalysts

infusion of bosutinib

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Oct 31, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment14

FDA Designations

No designations recorded

Clinical trial landscape

infusion of bosutinib · 1 trial · 1 indication

Phase 1 1
NCT02192294Absolute Bioavailability Of BosutinibHealthy
COMPLETED14 Analytics
PHASE1COMPLETED
Absolute Bioavailability Of Bosutinib
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Area under the Concentration-Time Curve (AUC)
96 hours

AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.

Secondary Endpoints

Maximum Observed Plasma Concentration (Cmax)
96 hours
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)
96 hours
Time to Reach Maximum Observed Plasma Concentration (Tmax)
96 hours
Unlock Study Endpoints

Study Design & Arms

MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
BosutinibEXPERIMENTAL -

Interventions

NameTypeDescription
Oral BosutinibDRUGa single dose of 500 mg oral bosutinib
Intravenous infusion of bosutinibDRUGa single dose of 120 mg of bosutinib intravenous infusion (1 hour)
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy male and/or female subjects (of non-childbearing potential). * Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study. * Subjects who are willing and able to comply with al...

Countries:United Kingdom
Unlock Eligibility Criteria

Frequently asked questions about infusion of bosutinib

What is bosutinib infusion used for?

Bosutinib infusion is a small molecule drug being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial in the United Kingdom. The drug is being investigated for its absolute bioavailability, which refers to the extent to which the drug reaches systemic circulation.

Who makes bosutinib infusion?

Bosutinib infusion is developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development, with one completed trial in healthy volunteers.

What phase is bosutinib infusion in?

Bosutinib infusion is in Phase 1 clinical development. It has one completed trial, NCT02192294, which was a Phase 1 study in healthy volunteers. The drug is investigational and has not been approved for any indication.

What clinical trials is bosutinib infusion in?

Bosutinib infusion has one clinical trial, NCT02192294, titled "Absolute Bioavailability Of Bosutinib." This Phase 1 study was completed in the United Kingdom and enrolled 14 healthy volunteers aged 18 years and older. The trial was uncontrolled and not randomized or double-blinded.

Is bosutinib infusion the same as bosutinib?

Bosutinib infusion is a formulation of bosutinib, a small molecule drug. The infusion is being studied for its absolute bioavailability in healthy volunteers. Bosutinib is also known by other names, but the specific alternative names are not provided in the available information.